- Molecular NameDihydrocodeine
- SynonymNA
- Weight301.386
- Drugbank_IDN/A
- ACS_NO125-28-0
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.74
- pka8.8
- LogD (pH=7, predicted)0.51
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.88
- LogSw (predicted, AB/LogsW2.0)2.52
- Sw (mg/ml) (predicted, ACD/Labs)1.28
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds1
- TPSA41.93
- StatusN/A
- AdministrationOral, subcutaneous, I.M., rectal, possiblly sublingual/buccal
- PharmacologyA semi-synthetic opioid analgesic developed in Germany in 1908 and put on the market in 1911. It is prescribed for pain, severe dyspnea, or as an antitussive, either alone or compounded with aspirin or paracetamol, as in co-dydramol. In some countries, controlled-release dihydrocodeine and/or the immediate release forumulations are used as an alternative to methadone in treatment of opioid dependency and addiction.
- Absorption_value89.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability20.0
- Protein bindingN/A
- Volume of distribution (VD)1 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMainly hepatic, through CYP3A4 and CYP2D6. It undergoes extensive first-pass metabolism in the gut wall or liver. Metabolism includes N-demethylation to form nordihydrocodeine, O-demethylation producing dihydromorphine, 6-keto reduction, and conjugation.
- Half life4 h
- ExcretionAfter an oral dose of 52 mg, 20 to 30% is excreted in the urine in 24 h; this is increased to about 35% when the urine is acid. After an intramuscular dose of about 43 mg under conditions of controlled acidic urinary pH, 40 to 60% is excreted in the urine in 24 h. About 30 to 45% of the urinary excreted material is conjugated.
- Urinary ExcretionN/A
- Clerance4 ml/min/kg
- ToxicityThe estimated minimum lethal dose is 0.5 g, but addicts may be able to tolerate up to ten times as much, whereas 25 mg may be fatal in children.
- LD50 (rat)N/A
- LD50 (mouse)LD50=132